Multiple myeloma
Conditions
Interventions
AI-MDT:None
Sponsors
The First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Age>=18 years; 2) Diagnosed as symptomatic multiple myeloma according to the IMWG 2016 criteria, and not receiving systemic anti-myeloma treatment; 3) Bone marrow disease caused by multiple myeloma has been confirmed by imaging (PET/CT, MR or CT); 4) Diagnosis period: from January 1, 2020 to June 30, 2024; 5) The patient has available and assessable myeloma-related indicators for efficacy, including blood M protein, urine M protein, serum free light chain, bone marrow plasma cell level or extramedullary plasma cell tumor; 6) Complete and usable baseline data, treatment plans and follow-up data are available.
Exclusion criteria
Exclusion criteria: 1) Patients with other primary malignancies who still require treatment; 2) Patients diagnosed with smoldering myeloma or monoclonal immunoglobulinosis of undetermined significance; 3) Pregnant or lactating women; 4) Patients with severely missing clinical data for reliable evaluation; 5) Patients deemed unsuitable for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of skeletal-related events; | — |
Countries
China
Contacts
Public ContactChen Bin
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed